Anne Eudes Jean Baptiste1, John Wagai2, Richard Luce3, Balcha Masresha4, Don Klinkenberg5, Irene Veldhuijzen5, Joseph Oteri6, Boubacar Dieng7, Obianuju Caroline Ikeonu2, Sule Meleh8, Audu Musa2, Fiona Braka2, Susan Hahné5, E A M Sanders5, Eelko Hak9. 1. World Health Organization (WHO), Country Office, Abuja, Nigeria. jeana@who.int. 2. World Health Organization (WHO), Country Office, Abuja, Nigeria. 3. World Health Organization (WHO), Inter-country Support Team for West Africa, Ouagadougou, Burkina Faso. 4. World Health Organization (WHO), African Regional Office, Brazzaville, Congo. 5. National Institute for Public Health and The Environment, Bilthoven, Netherlands. 6. National Primary Health Care Development Agency, Abuja, Nigeria. 7. Technical Assistance Consultant, Global Alliance for Vaccines and Immunizations, Abuja, Nigeria. 8. State Primary Health Care Development Agency, Maiduguri, Borno State, Nigeria. 9. Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.
Abstract
BACKGROUND: From January to May 2019, large measles outbreaks affected Nigeria. Borno state was the most affected, recording 15,237 suspected cases with the state capital of Maiduguri having 1125 cases investigated and line-listed by March 2019. In Borno state, 22 of the 27 Local Government Areas (LGAs or Districts), including 37 internally displaced persons (IDPs) camps were affected. In response to the situation, an outbreak response immunization (ORI) campaign was conducted in the 13 most affected LGAs. In addition to conventional vaccination teams, special teams were deployed in security compromised areas, areas with migrants, and for nomadic and IDPs. Here we describe the outbreak and the ORI campaign. We also assess the measles-containing vaccine (MCV) coverage and vaccine effectiveness (VE) in order to quantify the population-level impact. METHODS: We reviewed the ORI activities, and conducted an analysis of the surveillance and the outbreak investigation reports. We assessed VE of MCV by applying the screening-method. Sensitivity analyses were also conducted to assess the effect of final classification of cases on the VE of MCV. The MCV coverage was assessed by a post-campaign coverage survey after completion of the ORI through a quantitative survey in the 12 LGAs that were accessible. RESULTS: Of the total 15,237 reported measles cases, 2002 cases were line-listed and investigated, and 737 were confirmed for measles by week 9 of 2019. Of the investigated cases 67.3% (n = 1348) were between 9 and 59 months of age. Among the 737 confirmed cases, only 9% (n = 64) stated being vaccinated with at least 1 dose of MCV. The overall VE for MCV was 98.4% (95%CI: 97.8-98.8). No significant differences were observed in the VE estimates of lab-confirmed and epi-linked cases when compared to the original estimates. The aggregated weighted vaccination coverage was 85.7% (95% CI: 79.6-90.1). CONCLUSION: The experience in Borno demonstrates that adequate VE can be obtained in conflict-affected areas. In complex emergencies affected by measles outbreaks, health authorities may consider integration with other health strategies and the engagement of security personnel as part of the ORI activities.
BACKGROUND: From January to May 2019, large measles outbreaks affected Nigeria. Borno state was the most affected, recording 15,237 suspected cases with the state capital of Maiduguri having 1125 cases investigated and line-listed by March 2019. In Borno state, 22 of the 27 Local Government Areas (LGAs or Districts), including 37 internally displaced persons (IDPs) camps were affected. In response to the situation, an outbreak response immunization (ORI) campaign was conducted in the 13 most affected LGAs. In addition to conventional vaccination teams, special teams were deployed in security compromised areas, areas with migrants, and for nomadic and IDPs. Here we describe the outbreak and the ORI campaign. We also assess the measles-containing vaccine (MCV) coverage and vaccine effectiveness (VE) in order to quantify the population-level impact. METHODS: We reviewed the ORI activities, and conducted an analysis of the surveillance and the outbreak investigation reports. We assessed VE of MCV by applying the screening-method. Sensitivity analyses were also conducted to assess the effect of final classification of cases on the VE of MCV. The MCV coverage was assessed by a post-campaign coverage survey after completion of the ORI through a quantitative survey in the 12 LGAs that were accessible. RESULTS: Of the total 15,237 reported measles cases, 2002 cases were line-listed and investigated, and 737 were confirmed for measles by week 9 of 2019. Of the investigated cases 67.3% (n = 1348) were between 9 and 59 months of age. Among the 737 confirmed cases, only 9% (n = 64) stated being vaccinated with at least 1 dose of MCV. The overall VE for MCV was 98.4% (95%CI: 97.8-98.8). No significant differences were observed in the VE estimates of lab-confirmed and epi-linked cases when compared to the original estimates. The aggregated weighted vaccination coverage was 85.7% (95% CI: 79.6-90.1). CONCLUSION: The experience in Borno demonstrates that adequate VE can be obtained in conflict-affected areas. In complex emergencies affected by measles outbreaks, health authorities may consider integration with other health strategies and the engagement of security personnel as part of the ORI activities.
Authors: Michiel van Boven; Mirjam Kretzschmar; Jacco Wallinga; Philip D O'Neill; Ole Wichmann; Susan Hahné Journal: J R Soc Interface Date: 2010-04-14 Impact factor: 4.118
Authors: Walter A Orenstein; Lisa Cairns; Alan Hinman; Benjamin Nkowane; Jean-Marc Olivé; Arthur L Reingold Journal: Vaccine Date: 2018-01-11 Impact factor: 3.641
Authors: W A Orenstein; R H Bernier; T J Dondero; A R Hinman; J S Marks; K J Bart; B Sirotkin Journal: Bull World Health Organ Date: 1985 Impact factor: 9.408
Authors: Loveday Nkwogu; Faisal Shuaib; Fiona Braka; Pascal Mkanda; Richard Banda; Charles Korir; Samuel Bawa; Sule Mele; Mahmud Saidu; Hyelni Mshelia; Aliyu Shettima; Sisay G Tegegne; Yared G Yehualashet; Usman Adamu; Peter Nsubuga; Rui G Vaz; Alemu Wondimagegnehu Journal: BMC Public Health Date: 2018-12-13 Impact factor: 3.295
Authors: Thomas Jideofor Ogbu; Sarah Elizabeth Scales; Maria Moitinho de Almeida; Joris Adriaan Frank van Loenhout; Niko Speybroeck; Debarati Guha-Sapir Journal: Arch Public Health Date: 2022-06-28
Authors: Terna Nomhwange; Abede Mohammed; Anne Eudes Jean Baptiste; Audu Musa; Abdulhakeem Yusuf; Mohammed Yusuf; John Wagai; Aliyu Shettima; Sule Meleh; Richard Banda; Fiona Braka; Richard Luce; Balcha Masresha Journal: Pan Afr Med J Date: 2022-02-06